Diagnostic test could help doctors refine prostate cancer treatment with abiraterone
A novel diagnostic test could enable doctors to identify which prostate cancer patients would benefit from more intensive treatment with drugs like abiraterone, while sparing others from unnecessary side effects. The test aims to address the challenge of tailoring treatment for prostate cancer, which affects over 1 million men worldwide and behaves differently in each patient.
